

1 **Fetal therapy model of myelomeningocele with three-dimensional skin**
2 **using amniotic fluid cell-derived induced pluripotent stem cells**

3

4 Kazuhiro Kajiwara^{1,4}, Tomohiro Tanemoto⁵, Seiji Wada², Jurii Karibe¹, Norimasa
5 Ihara¹, Yu Ikemoto¹, Tomoyuki Kawasaki¹, Yoshie Ohishi¹, Osamu Samura⁴, Kohji
6 Okamura³, Shuji Takada³, Hidenori Akutsu¹, Haruhiko Sago², Aikou Okamoto⁴, and
7 Akihiro Umezawa^{1*}

8

9 Department of ¹Reproductive Biology, ²Maternal-Fetal, Neonatal and Reproductive
10 Medicine, and ³Systems BioMedicine, National Research Institute for Child Health and
11 Development, Tokyo 157-8535, Japan

12 ⁴Department of obstetrics and gynecology, The Jikei University School of Medicine,
13 Tokyo 105-8471, Japan

14 ⁵Department of Medical Science, Chiba University Graduate School of Medicine, Chiba
15 260-0856, Japan

16

17 Running title: Application of iPSCs for a fetal therapy

18

19 *Correspondence should be directed to:

20 Akihiro Umezawa, M.D., Ph.D.

21 Department of Reproductive Biology,

22 National Research Institute for Child Health and Development

23 2-10-1 Okura, Setagaya,

24 Tokyo, 157-8535 Japan

25 Phone: +81-3-5494-7047

26 Fax: +81-3-5494-7048

27 E-mail: umezawa@1985.jukuin.keio.ac.jp

28

29

1 **Abstract**

2 Myelomeningocele (MMC) is a congenital disease without genetic abnormalities.
3 Neurological symptoms are irreversibly impaired after birth. No effective treatment has
4 been reported to date. Only surgical repairs have reported so far. In this study, we
5 performed antenatal treatment of MMC with an artificial skin using induced pluripotent
6 stem cells (iPSCs) generated from a patient with Down syndrome (AF-T21-iPSCs) and
7 twin–twin transfusion syndrome (AF-TTTS-iPSCs) to a rat model. We manufactured
8 three-dimensional skin with epidermis generated from keratinocytes derived from
9 AF-T21-iPSCs and AF-TTTS-iPSCs and dermis of human fibroblasts and collagen
10 type I. For generation of epidermis, we developed a novel protocol using Y-27632 and
11 epidermal growth factor. The artificial skin was successfully covered over MMC defect
12 sites during pregnancy, implying a possible antenatal surgical treatment with iPSC
13 technology.
14

1 **Introduction**

2 Myelomeningocele (MMC) is the most common neural tube defect characterized by a
3 skin defect in addition to defects of the midline vertebra and dura mater. Under these
4 conditions, the spinal cord is exposed to the external environment. Although MMC is
5 compatible with survival, this condition ranks as one of the most severe birth defects,
6 with the manifestation of sequelae that affect both the central and peripheral nervous
7 systems, leading to lifelong paralysis and dysfunction of the bladder and bowel for
8 which no cures exist. The two-hit hypothesis postulates irreversible neurological deficits
9 during pregnancy. First, a failure of primary neurulation results in the neural tube defect.
10 Second, the subsequent destruction of the exposed neural tissue is attributed to the
11 chemical damage by amniotic fluid (AF) containing meconium and to the physical
12 damage caused by the direct trauma (Heffez et al., 1990; McLone and Knepper, 1989;
13 Michejda, 1984). Therefore, fetal intervention is focused to prevent progressive
14 neurological damage *in utero* (Bruner et al., 2004; Johnson et al., 2003; Sutton et al.,
15 1999; Tubbs et al., 2003; Tulipan et al., 1999; Tulipan et al., 2003; Walsh et al., 2001).
16 The first human randomized-controlled clinical trial entitled the “Management of
17 Myelomeningocele Study (MOMS)” has found that intrauterine repair of fetal MMC
18 improves the neurological prognosis compared with postnatal MMC repair (Adzick et
19 al., 2011). However, the MOMS trial also proved that severe complications such as
20 preterm birth, premature rupture of the membrane, and placental abruption and uterine
21 wall dehiscence at the repair site increased due to a large incision of the uterine wall.
22 Moreover, the skin defect is too large to allow skin closure in 20%–30% of fetuses with
23 MMC (Mangels et al., 2000). Although several less invasive methods that prevent
24 leaking of cerebral spinal fluid with coverage of the exposed spinal cord using various
25 coverage materials, such as gelatin sponge incorporating basic fibroblast growth factor
26 and autologous amniotic membrane, have been reported, improvement of neurological
27 function remains insufficient because insufficient recovery of neural damage occurs
28 during pretreatment (Brown et al., 2014; Kohl et al., 2006; Kohl et al., 2009; Watanabe
29 et al., 2010; Watanabe et al., 2011). Thus, the development of a less invasive method is
30 required to be applied during earlier gestation.

31

32 Coverage of a skin defect by a three-dimensional (3D) skin enables fetal intervention to

1 be not only less invasive but also completed by an earlier term of pregnancy because
2 autologous cultured skin transplantation enhance wound healing such as autologous
3 skin transplantation for patients with severe burns (Pham et al., 2007). Moreover, 3D
4 skin may grow in harmony with the fetal growth during all pregnancy periods. However,
5 it is difficult to provide available autologous skin grafts for a fetus with MMC.
6 Furthermore, the strong demand far outstrips the current supply of skin graft. Therefore,
7 we hypothesize that induced pluripotent stem cells (iPSCs) can be an ideal new material
8 for autologous skin transplantation. The first clinical therapy using human iPSCs treated
9 a Japanese woman with macular degeneration (Sivan et al., 2016). A great deal of
10 research is currently in progress to facilitate therapy for patients with intractable
11 diseases, such as Parkinson' disease and spinal cord injury (Cherry and Daley, 2012,
12 2013). iPSCs can provide therapeutic potential for tissue repair and regeneration in
13 combination with *in vitro* differentiation. The use of iPSCs in clinical application has
14 largely been welcomed by society because the use of these cells avoids the substantial
15 ethical concerns and immune rejection.

16
17 In the present study, we generated human iPSCs from amniotic fluid cells (AFCs) using
18 feeder-free, xeno-free, and integration-free systems. To verify that iPSCs could be
19 generated from fetuses with severe fetal disease, we chose two major fetal diseases,
20 twin–twin transfusion syndrome (TTTS) and trisomy 21 (T21): TTTS is one of the most
21 serious complications of monochorionic multiple gestations; fetal intervention is most
22 frequently performed, and trisomy 21 is the most common chromosome abnormality
23 among liveborn infants. To apply iPSC-based cell therapy during earlier gestational age,
24 we established an effective protocol for differentiation of iPSCs into keratinocytes by
25 the addition of Y-27632 and epidermal growth factor (EGF). We successfully
26 established a novel surgical approach in the fetal rat model of MMC using reconstructed
27 3D skin with iPSC-derived keratinocytes (iPSC-KC) and investigated the effect of
28 transplantation of 3D skin.

29

30 **Materials and Methods**

31 **Ethical statement**

32 The protocol for the use of human cells in the present study was approved by the

1 Institutional Review Board of the National Research Institute for Child Health and
2 Development of Japan and was in full compliance with the Ethical Guidelines for
3 Clinical Studies (Ministry of Health, Labor, and Welfare).

4

5 **Human cells**

6 AF was obtained from fetus with Down syndrome and TTTS, with both conditions
7 associated with polyhydramnion. In case of TTTS, AF was obtained at the time of
8 fetoscopic laser surgery at gestational ages ranging from the 19th to 26th weeks. In the
9 cases of Down syndrome, AF was obtained by amnioreduction at 29 weeks of gestation.
10 Cells were obtained by the centrifugation of 20-ml AF at 1,500 rpm for 10 min after
11 filtration through a 100- μ m filter. The supernatant was removed, and the precipitates
12 were seeded in 60-mm tissue culture dishes, which were precoated with 0.1% gelatin.
13 These cells were incubated at 37°C under 5% humidified CO₂ in 4 ml of
14 AmnioMAX™-II Complete Medium (Invitrogen, cat. no. 11269-016). Cell clusters
15 were emerged at 6–7 days after seeding. Nonadherent cells were discarded, and the
16 media was changed every 2 days. When the cultures reached subconfluence, the cells
17 were harvested with a trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Wako,
18 cat. no. 209-16941) and replated at a ratio 1:8 in a 60-mm dish. These cells were
19 cultured and passaged routinely at 70%–80% confluence. The cells at passages 3–4
20 were used for the generation of iPSCs.

21

22 HDK1-K4DT, an immortalized keratinocyte, was grown in a keratinocyte serum-free
23 medium (KSFM) (Invitrogen, cat. no. 17005-042) and supplemented with 10 μ M
24 Y-27632 (Wako, cat. no. 251-00514) (Egawa et al., 2012). Subconfluent cultures of
25 HDK1-K4DT were passaged at a ratio 1:6. HDK1-K4DT at less than passage 20 was
26 used for organotypic culture. HFF2, an immortalized fibroblast, was grown in
27 Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine
28 serum (FBS) (Tatsumi et al., 2006).

29

30 **Generation of feeder-free iPSCs**

31 AF-derived cells (AFCs) were seeded at 6×10^5 /well in a six-well plate and maintained

1 in AmnioMAXTM-II Complete Medium. Three episomal vectors encoding six factors
2 (L-MYC, KLF4, OCT4, SOX2, LIN28, and short-hairpin RNA for P53) (addgene, cat.
3 no. 27077, 27078, 27079) were electroporated into the AFCs on day 0 as previously
4 described (Okita et al., 2011). On day 5, transfected cells were passaged and seeded at
5 1.3×10^6 /dish onto Vitronectin (VTN) (Life Technologies, cat. no. A14701SA)-coated
6 100-mm plates in Essential 8 (E8) medium (Life Technologies, cat. no. A14666SA),
7 and the medium was changed every 2 days. We observed the appearance of human
8 embryonic stem cell (ESC)-like colonies 30–50 days after electroporation. For
9 feeder-free cultures, plates were coated with 0.5 g/cm^2 VTN at room temperature for 1 h.
10 iPSCs were maintained in E8 Medium on VTN-coated dishes and passaged using
11 0.5 mM EDTA in PBS. Colonies with flat, human ESC-like morphology were expanded
12 and maintained successfully for more than 70 passages.

13

14 **RT-PCR**

15 Total RNA was isolated from cells using the RNeasy Plus micro Kit (Qiagen, cat. no.
16 74004), and DNA was removed by DNase treatment (Qiagen, cat. no. 79254).
17 Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using
18 Superscript III reverse transcriptase (Invitrogen, cat. no. 18080-085) with oligo (dT)
19 primer according to the manufacturer's instructions. Template cDNA was PCR
20 amplified with gene-specific primer sets (Supplemental Table S1).

21

22 **Quantitative RT-PCR**

23 RNA was extracted from cells using the RNeasy Plus Micro kit (Qiagen, cat. no. 74004).
24 An aliquot of total RNA was reverse transcribed using an oligo (dT) primer (Invitrogen,
25 cat. no. 18418-20). For the thermal cycle reactions, the cDNA template was amplified
26 (Applied Biosystems[®] QuantstudioTM 12K Flex Real-Time PCR System) with
27 gene-specific primer sets using the Platinum Quantitative PCR SuperMix-UDG with
28 ROX (Invitrogen, cat. no. 11743-100) under the following reaction conditions: 40
29 cycles of PCR (95°C for 15 s and 60°C for 1 min) after an initial denaturation (95°C for
30 2 min). Fluorescence was monitored during every PCR cycle at the annealing step. The
31 authenticity and size of the PCR products were confirmed using a melting curve
32 analysis (using software provided by Applied Biosystems). mRNA levels were

1 normalized using glyceraldehyde-3-phosphate dehydrogenase as a housekeeping gene.

2

3 **Immunocytochemical analysis**

4 Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 min at 4°C. After
5 washing with PBS and treatment with 0.1% Triton X-100 (Sigma-Aldrich, cat. no.
6 T8787-100ML) for 10 min at 4°C, cells were pre-incubated with 5% normal goat serum
7 (Dako, cat. no. X0907) in PBS for 30 min at room temperature, following which they
8 were reacted with primary antibodies in blocking buffer for 24 h at 4°C. After washing
9 with PBS, cells were incubated with fluorescently coupled secondary antibodies;
10 anti-rabbit or anti-mouse IgG conjugated with Alexa 488 or 546 (1:1000) in blocking
11 buffer for 30 min at room temperature. The nuclei were stained with
12 4',6-diamidino-2-phenylindole (DAPI) (Biotium, cat. no. 40043). All images were
13 captured using confocal microscopy (LSM 510 and LSM 510 META laser scanning
14 microscope). Antibody information is provided in Supplemental Table S2.

15

16 **Karyotypic analysis**

17 Karyotypic analysis was performed at the Nihon Gene Research Laboratories Inc.
18 (Sendai, Japan). Metaphase spreads were prepared from cells with 100 ng/ml of
19 Colcemid (Karyo Max, Gibco Co. BRL) treatment for 6 h. The cells were fixed with
20 methanol:glacial acetic acid (2:5) three times and dropped onto glass slides (Nihon
21 Gene Research Laboratories Inc.). Chromosome spreads were Giemsa banded and
22 photographed. Twenty metaphase spreads were analyzed for each sample and
23 karyotyped using a chromosome imaging analyzer system (Applied Spectral Imaging,
24 Carlsbad, CA).

25

26 **Short tandem repeat analysis**

27 Short tandem repeat analysis was performed at BEX CO., LTD. Using the genomic
28 DNA extracted from iPSCs generated from patients with TTTS (AF-TTTS-iPSCs) and
29 TTTS (AF-TTTS-iPSCs), 16 microsatellite markers were amplified by PCR with
30 microsatellite-specific primers.

31

1 **Whole-exome sequencing**

2 Approximately 2.0 µg of genomic DNA from each cell sample was sonicated to provide
3 an average fragment size of 200–300 bp on a Covaris S220 instrument. After 5 cycles of
4 PCR amplification, capture and library preparation were performed with Agilent
5 SureSelect Human All Exon V5 + lincRNA (50 Mb), followed by washing, elution, and
6 additional 12-cycle PCR amplification to attach index adaptors. Enriched libraries were
7 sequenced on an Illumina HiSeq 2500 operated in 100-bp paired-end mode. Image
8 analyses and base calling on all lanes of data were performed using bcl2fastq 1.8.4 with
9 default parameters.

10

11 **Read mapping and variant analysis**

12 Reads from the sample were first trimmed by removing adapters using cutadapt 1.7.1
13 and low-quality bases at ends using a custom script. Then, they were aligned to the
14 hs37d5 sequence (hg19 and decoy sequences) using the Burrows–Wheeler Aligner
15 0.7.10. Mapped reads were converted from SAM to BAM using SAMtools 1.2 and
16 processed by Picard 1.109 to eliminate PCR duplicate reads. The Genome Analysis
17 Toolkit (GATK) 3.4 was then used to perform local realignment with known indel sites
18 and map quality score recalibration to produce calibrated BAM files. Multi-sample
19 callings for single-nucleotide variants (SNVs) were made by GATK. The annotated
20 variant call format files were then filtered using GATK with a stringent filter setting and
21 custom scripts. Annotations of detected variants were made using ANNOVAR based on
22 GRCh37. Genotypes of control samples were shuffled for each variant from a
23 perspective of protection of personal information.

24

25 **Teratoma formation**

26 iPSCs were harvested by accutase treatment, collected into tubes, and centrifuged. The
27 same volume of basement membrane matrix (BD Biosciences, cat. no. 354234) was
28 added to the cell suspension. The cells ($>1 \times 10^7$) were subcutaneously inoculated into
29 immunodeficient nude mice (BALB/cAJcl-*nu/nu*) (CREA, Tokyo, Japan). After
30 6–8 weeks, the resulting tumors were dissected and fixed with PBS containing 4% PFA.
31 Paraffin-embedded tissue was sliced and stained with hematoxylin and eosin. The

1 operation protocols were accepted by the Laboratory Animal Care and the Use
2 Committee (A2003-002-C13-M05).

3

4 **Fluorescence-activated cell sorting analysis**

5 The expression of cell surface markers on AFCs cultured in the amniomax II at passage
6 3 and keratinocytes derived from iPSCs were analyzed by flow cytometry. The AFCs
7 and iPSC-derived keratinocytes were harvested by Trypsin-EDTA solution treatment
8 and fixed with 2% PFA/PBS for 15 min at RT. After PBS wash, cells were permeabilized
9 with 0.1% saponin (Wako, cat. no. 192-08851) and blocked with 5% goat serum. Primary
10 antibodies were incubated for 1 h in PBS with 1% bovine serum albumin. After washing
11 with PBS, cells were incubated with fluorescently coupled secondary antibodies;
12 anti-rabbit or anti-mouse IgG conjugated with Alexa 488 (1:1000) for 30 min at room
13 temperature. Secondary stain cells were analyzed on a BD LSR Fortessa (BD
14 Biosciences).

15

16 **Protocol for differentiating iPSCs into keratinocytes**

17 To induce differentiation, small clumps of undifferentiated iPSCs were subcultured onto
18 a VTN-coated 10-mm dish in E8 medium on day 1 (protocol A). For comparison of
19 differentiation protocols, single cells of iPSCs were subcultured onto a VTN-coated
20 circle patterned CytoGraph (Dai Nippon printing Co., Ltd.) dish in E8
21 medium-supplemented 10- μ M Y-27632 (Wako, cat. no. 251-00514) (protocol B) on
22 day1. iPSCs were then incubated in defined keratinocyte serum-free medium (DKSFM)
23 (Invitrogen, cat. no. 10744-019) supplemented with 1 μ M all-trans retinoic acid (RA)
24 (Wako, cat.no. 182-01111) and 10 ng/ml bone morphogenetic protein 4 (BMP4) (R&D
25 systems. cat. no. 314-BP-010/CF) for 4 d. After 4 d, iPSCs were maintained in DKSFM
26 supplemented with 20 ng/ml EGF (R&D systems, cat. no. 236-EG-200) until 14 days
27 and passaged onto a 0.03 mg/ml coating of type I collagen (Advanced Biomatrix, cat.
28 no. 5005-B) and 0.01 mg/ml fibronectin (Sigma Aldrich, cat. no. F0895-1MG)-coated
29 dish in DKSFM supplemented with 10 μ M Y-27632 (Wako, cat. no. 251-00514) and
30 20 ng/ml EGF. iPSC-derived keratinocytes were seeded at 3×10^4 /cm² cells and
31 enriched by rapid adherence to fibronectin and type I collagen-coated dishes for

1 15–30 min at room temperature. Nonadherent cells were discarded, and rapidly attached
2 cells were cultured. EB method (protocol C) was performed as described previously
3 (Bilousova et al., 2011). Embryonic bodies (EBs, n=100) were formed from 5×10^4
4 iPSCs on a Petri dish in embryonic stem cell medium without basic fibroblast growth
5 factor (ESC-no-bFGF medium). After 2 days, 30 EBs were transferred to a new Petri
6 dish with ESC-no-bFGF medium containing 1- μ M RA for three days in suspension
7 culture. EBs were then transferred onto a type-IV (Sigma-Aldrich, cat. no.
8 C7521-10MG)-coated 100-mm dish with ESC-no-bFGF medium containing 25-ngml⁻¹
9 BMP4. After 3 days, the medium was switched to DKSFM, and the plated EBs were
10 cultured for six days. EB remnants were removed by vacuum aspiration, and
11 iPSC-derived keratinocytes were subcultured onto type-IV-coated 100-mm dish and
12 selected rapid attachment to type-IV-coated dish for 15 minutes at room temperature in
13 DKSFM.

14

15 **Generation of 3D skin equivalent**

16 3D skin was generated according to a previously described protocol (Tsunenaga et al.,
17 1994). To prepare the dermal equivalent, type I collagen (Koken Co., cat. no. IPC-50)
18 and DMEM plus 10% FBS containing 1×10^6 HFF2s were mixed and poured into an
19 untreated 60-mm Petri dish while cooling and allowed to gel at 37°C for 1 h.
20 Contraction of the collagen gel was facilitated by pulling the gel from the surface of the
21 Petri dish. The medium was changed every 2 or 3 d for 7 d. HDK1-K4DT or
22 iPSC-derived keratinocytes were plated at 2×10^5 or 1×10^6 cells inside in a glass ring
23 (10 mm diameter) on the surface of the contracted collagen gel, which was plated onto
24 polyethylene terephthalate membranes (Corning, cat. no. 35-3493). iPSC-derived
25 keratinocytes were grown in DKSFM supplemented with 10 μ M Y-27632 and 20 ng/ml
26 EGF for 2 days, following which they were exposed to air in a 1:1 mixture of KSFM
27 and DMEM plus 10% FBS, in which the Ca²⁺ concentration was adjusted to 1.8 mM.
28 The medium was changed every 2 or 3 days. Multilayered 3D cultures of keratinocytes
29 were obtained by days 14–21.

30

1 **Animal preparation and RA exposure**

2 The procedure for creating MMC defects in fetal rats was based on the protocol
3 described earlier (Danzer et al., 2005; Watanabe et al., 2010). Briefly, time-dated
4 Sprague-Dawley rats (CLEA Japan, Tokyo or Sankyo Labo Service Co, Tokyo) were
5 used. After being exposed to isoflurane (Wako, cat. no. 099-065-71), anesthetized rats
6 were fed 60 mg/kg all-trans RA (Wako, Tokyo, cat. no. 182-01111) dissolved in olive
7 oil (10 mg/ml) at embryonic day 10 (E10).

8

9 **Surgical procedure**

10 Fetal intervention of RA-exposed Sprague-Dawley rats was performed at E20. Pregnant
11 rats were anesthetized by isoflurane, and an abdominal midline incision was made to
12 expose the uterine horns. The MMC defect was confirmed through the uterus under
13 direct vision, and a small incision of the uterine wall and amniotic membranes was
14 made directly above the defected site. 3D skin was transplanted into the area of defected
15 skin. Beriplast P Combi-Set (CSL Behring, cat. no. 87799) was used for tissue adhesion.
16 The hysterectomy site was closed by purse-string suture with 6-0 silk (Natsume
17 Seisakusho, cat. no B10-60). The uterus was returned to the abdomen, and the
18 abdominal incision site was closed by running suture. The fetuses were harvested by
19 cesarean section at E22. Pregnant rats were then euthanized by cervical dislocation
20 under anesthesia with isoflurane. The transplantation site was dissected and processed
21 for histological and immunohistochemistry analysis. The primary antibody list is
22 provided in Supplemental Table S2. Appropriate Alexia488 or alexa594-conjugated
23 secondary antibody was used with DAPI nuclear counterstain. The operation protocols
24 were accepted by the Laboratory Animal Care and the Use Committee
25 (A2015-003-C01).

26

27 **Statistical analysis**

28 Each experiment was repeated at least three times, and the data are presented as the
29 mean \pm SD of the mean. Statistical significance was determined by the student's *t* test.
30 $p < 0.05$ was considered statistically significant.

31

1 **Results**

2 **Derivation and characterization of AFCs in patients with polyhydramnion**

3 To examine whether iPSCs could be efficiently generated from human AFCs derived
4 from patients with the serious disease coexisting polyhydramnion, we focused on two
5 fetal diseases, namely TTTS and Down syndrome. Human AFCs were isolated from
6 patients with TTTS (TTTS-AFC) and Down syndrome (T21-AFC) with the consents of
7 subjects and the Ethical Review Board of the National Research Institute for Child
8 Health and Development. AF was obtained through amniocentesis under sterile
9 conditions during amnioreduction for therapy of polyhydramnion. Approximately 20 ml
10 of AF is sufficient to obtain AFCs. The average number of viable cells was
11 $0.356 \times 10^6/\text{ml} \pm 0.227 \times 10^6/\text{ml}$ (mean \pm standard deviation [SD]). The AFCs showed
12 heterogeneous morphologies and reached confluence by 10 days after cell seeding
13 (Figure 1A). Flow cytometry at passage 3 revealed that CD29, CD44, CD73, and
14 human leukocyte antigen (HLA)-ABC [major histocompatibility complex (MHC)
15 class I], were strongly positive; CD117 was rarely positive (0.8%), whereas CD14,
16 CD19, CD34, HLA-DR, DP, and DQ (MHC class II) were negative (Figure 1B).
17 Quantitative real-time polymerase chain reaction (qRT-PCR) analysis revealed trace
18 amounts of OCT3/4, NANOG, and SOX2, compared with endometrial-derived
19 mesenchymal stem cells (EDOM-MSCs) (Figure 1C). These results indicate that AFCs
20 derived from polyhydramnion have a similar population to a normal volume of AF (De
21 Coppi et al., 2007; Li et al., 2009; Tsai et al., 2004; You et al., 2008).

22

23 **Generation of human iPSCs from AFCs of patients with TTTS and Down syndrome**

24 AFCs at passages 3–4 were transfected with episomal vectors carrying six
25 reprogramming factors (L-MYC, KLF4, OCT4, SOX2, LIN28, and short-hairpin RNA
26 for P53) by electroporation. After electroporation, AFCs were subcultured into
27 VTN-coated plates in chemically defined and serum-free Essential 8 medium. We
28 observed the appearance of human embryonic stem cell (hESC)-like colonies
29 30–50 days after electroporation. Colonies with human ESC-like morphology expanded
30 and grew as flat colonies with large nucleo-cytoplasmic ratios with a high level of
31 alkaline phosphatase activity (Figure 2A). No significant differences in proliferation

1 rates were detected between AF-T21-iPSCs and AF-TTTS-iPSCs. Neither cessation of
2 cell proliferation such as senescence nor apoptosis/cell death was detected during
3 cultivation through 70 passages. The reprogramming efficiency was 0.1% and 0.3% in
4 AF-TTTS-iPSCs and AF-T21-iPSCs, respectively.

5 6 **Characterization of AF-T21-iPSCs and AF-TTTS-iPSCs**

7 Both AF-TTTS-iPSCs and AF-T21-iPSCs expressed multiple pluripotency markers,
8 including nuclear transcription factors OCT3/4, NANOG, SOX2, as well as surface
9 antigen stage-specific embryonic antigen 4 (SSEA-4) and tumor-related antigen
10 (TRA)-1-60 and TRA-1-81 (Figure 2B). qRT-PCR analysis showed that endogenous
11 pluripotency marker genes, including OCT3/4, SOX2, NANOG, telomerase reverse
12 transcriptase (TERT), and DNA methyltransferase 3 beta (DNMT3B), were activated in
13 human iPSCs to a similar extent of those in control hESCs (SEES2) (Figure 2C), and
14 the transgenes were fully silenced in AF-T21-iPSCs and AF-TTTS-iPSCs. We next
15 examined the ability for *in vitro* differentiation by examining the expression of germ
16 layer-specific markers in the embryonic body formation. Our analysis demonstrated that
17 AF-T21-iPSCs and AF-TTTS-iPSCs were capable of differentiating into all three germ
18 layers *in vitro* (Figure 2D). To examine pluripotency of iPSC clones, teratoma formation
19 was performed by implantation of AF-T21-iPSCs and AF-TTTS-iPSCs at the
20 subcutaneous tissue of immunodeficient nude mice. Three independent AF-T21-iPSCs
21 and AF-TTTS-iPSCs clones induced teratomas within 6–8 weeks after implantation.
22 Histological analysis of paraffin-embedded sections demonstrated that all three primary
23 germ layers were generated as shown in Figure 2E. Thus, all AF-T21-iPSCs and
24 AF-TTTS-iPSCs clones examined had potential for multilineage differentiation *in vivo*.
25 Although teratoma derived from AF-T21-iPSCs showed the presence of
26 neuroblastoma-like tissue (Supplemental Figure S1A) and liver tissue with a vacuolar
27 structure (Supplemental Figure S1B), Down syndrome-specific findings were not
28 detected. Karyotypic analyses revealed that the AF-TTTS-iPSCs clones had normal
29 karyotypes (Figure 2F), whereas the AF-T21-iPSCs clones had trisomy 21 (Figure 2G).
30 Analysis of 16 patterns of the short tandem repeat (STR) site revealed that all STR sites of
31 AF-TTTS-iPSCs and AF-T21-iPSCs matched to those of their parental TTTS-AFC and
32 T21-AFC (Supplemental Figure S1C).

1

2 **Whole-exome analysis of T21-iPSCs**

3 The whole-exome analysis, wherein our sample was compared with the GRCh37
4 reference sequence, detected a heterozygous single-nucleotide variant (SNV) in the
5 *CRELD1* focus. The C-to-G substitution (rs2302787), which results in a Pro-to-Arg
6 alteration, was situated in exon 4. Several mutations of *CRELD1* have been reported to
7 contribute to occurrence of cardiac atrioventricular septal defects in Down syndrome
8 (Maslen et al., 2006). To know whether the alteration is deleterious, SIFT and
9 Polyphen2 were employed. The former makes influence from similarity of amino acid
10 sequences and gives scores close to zero when a variant is damaging, whereas the latter
11 predicts effects of not only sequences but also 3D structures and provides scores close
12 to 1.0 when a variant is intolerant. The scores for the variants were 0 and 0.999,
13 respectively, suggesting a notable variant. Although its global allele frequency was
14 1.0%, higher frequency of 4.5% was documented for the Japanese population in the
15 1000 Genomes project (Supplemental Table S3).

16

17 **Generation and characteristics of iPSC-derived keratinocytes**

18 We first attempted to generate iPSC-derived keratinocytes (iPSC-KC) based on the
19 prior differentiation protocol (Bilousova et al., 2011; Guenou et al., 2009; Itoh et al.,
20 2011; Metallo et al., 2008; Veraitch et al., 2013) using RA to promote ectodermal fate
21 and BMP4 to block neural fate. To define the effective differentiation protocol, we
22 compared differentiation efficiencies among three different protocols including direct
23 differentiation using VTN-coated dish (protocol A), CytoGraph-coated dish
24 (protocol B), and embryoid body method (protocol C) (Figure 3A). Protocols A and B
25 were differed in coating agent. In protocol A, we modified the previously reported
26 protocol (Itoh et al., 2011) by replacing matrigel with a human recombinant protein
27 using VTN.

28 During direct differentiation (protocols A and B), cell senescence was observed at
29 day 30, and these cells could not proliferate after the first passage. The number of
30 keratinocyte-like cells decreased after 17 days and β -galactosidase staining revealed that
31 cellular senescence was observed over 17 days, resulting in an exacerbated cellular state
32 (Figure 3B). Therefore, the first passage was performed at 14–17 days in protocols A

1 and B, respectively.

2

3 **Effect of Y-27632 on iPSC-KCs**

4 Although we detected keratinocyte-like cells during passage 1 of protocols A, B, and C,
5 we examined additional factors to obtain a sufficient number of iPSC-KC and found
6 that Y-27632 was critical. Y-27632 is an inhibitor of Rho kinase that increases the
7 long-term proliferative capacity of primary keratinocytes and promotes the
8 differentiation of human bone marrow MSCs into keratinocyte-like cells (Chapman et
9 al., 2010; Chapman et al., 2014; Li et al., 2015; Supryniewicz et al., 2012).
10 Keratinocytes derived from iPSCs grown in the presence of Y27632 showed improved
11 cell growth. The comparison of immunostaining of Keratin 14 (KRT14) at passage 2
12 with protocols A, B, and C revealed that the percentage of KRT14-positive cells
13 reached 48.08%, 39.24%, and 23.62% in protocol A, B, and C, respectively, indicating
14 that protocol A is most suitable for iPSC-KC proliferation (Figure 3C, 3D). Therefore,
15 during subsequent experiments, differentiation of iPSCs into keratinocytes was
16 performed by protocol A.

17

18 **Effect of EGF on iPSC-KCs**

19 iPSC-KCs treated with Y-27632 showed improved cell growth; however, cell
20 proliferation remained insufficient, required more than 2 weeks to obtain a sufficient
21 cell number. To promote cell proliferation with a high expression level of epithelial
22 markers, we examined iPSC-KCs to investigate the effect of EGF. iPSC-KCs treated
23 with EGF and Y-27632 for 9 days after first passage (starting cell number was
24 1×10^5 /well) showed markedly improved cell growth compared with the cells treated
25 with Y-27632, whereas the cell number of EGF-treated iPSC-KCs without treatment of
26 Y-27632 did not proliferate at all, indicating that the combination of EGF and Y-27632
27 is important for the cell growth of iPSC-KCs (Figure 3E). Although iPSC-KCs grown in
28 KSFM showed a higher cell growth than that grown in DKSFM (Figure 3E), we used
29 DKSFM for subsequent experiments as it is chemically defined and optimized for
30 growth and expansion of human keratinocytes without the potential contamination
31 derived from animal serum.

1

2 We further analyzed gene expression levels of KRT14 in iPSC-KC at passage 1 and
3 found that iPSC-KCs treated with EGF and Y-27632 expressed KRT14 at a higher level
4 than those treated with Y-27632 alone (Figure 3F). Flow cytometric analysis also
5 showed that KRT14-positive population increased in cell number and intensity by
6 addition of Y-27632 and EGF (Supplemental Figure S2A). Treatment with EGF for day
7 4 to 14 resulted in a marginal yet significantly higher expression of KRT14 (Figure 3G).
8 Y-27632 was not included for day 4 to 14 because Y-27632-treated iPSC-KCs before
9 the first passage showed a higher expression of OCT3/4 and NANOG (Figure 3G).
10 SSEA4-positive undifferentiated iPSCs were successfully removed by treatment of EGF
11 and Y-27632 after the first passage as confirmed by flow cytometric analysis
12 (Supplemental Figure S2B). As for the growth medium, DKSM was used throughout
13 the differentiation process (Supplemental Figure S2C). Taken together, we concluded
14 that differentiation efficiency of iPSC-KCs was most effective in protocol A using
15 DKSM supplemented EGF and Y-27632, as shown in Figure 3H.

16

17 **Characterization of keratinocytes derived from iPSCs**

18 In our protocol, overall induction periods were further reduced compared with
19 previously reported protocols (Guenou et al., 2009; Itoh et al., 2011; Itoh et al., 2013),
20 and iPSC-KCs were successfully increased and could be expanded for greater than five
21 passages at least. Interestingly, in terms of proliferative and differentiation abilities,
22 both Y-27632 and EGF were required for the generation of iPSC-KC. Y-27632 was
23 more of affecting the proliferative ability, and EGF was more of affecting the terminal
24 differentiation. Keratinocytes derived from AF-TTTS-iPSCs (TTTS-iPSC-KCs) and
25 AF-T21-iPSCs (T21-iPSC-KCs) showed keratinocyte-like morphology at passage 4 like
26 HDK1-K4DT (Figure 4A). KRT14 gradually increased for each passage (Figure 4B).
27 Transcriptional analysis by qRT-PCR showed that the gene expression levels of KRT14,
28 KRT18, p63, OCT3/4, and NANOG of TTTS-iPSC-KCs and T21-iPSC-KCs at
29 passage 4 reached to those in HDK1-K4DT (Figure 4C). Interestingly, T21-iPSC-KCs
30 showed higher expression of terminal differentiation markers such as INVOLUCRIN
31 and FILAGGRIN than TTTS-iPSC-KCs (Figure 4D). This result is consistent with the
32 clinical features of hyperkeratosis that are frequently observed in patients with Down

1 syndrome. Immunostaining revealed the expression of KRT14, p63, and laminin 5 both
2 in TTTS-iPSC-KCs and in T21-iPSC-KCs (Figure 4E). Moreover, keratin 10 (KRT10)
3 and involucrin, markers of differentiated keratinocytes of the suprabasal layer, were
4 induced under a high calcium condition. As expected, the number of involucrin-positive
5 T21-iPSC-KCs increased under a low calcium condition. Keratin 15 (KRT15), a marker
6 of epithelial stem cells in the hair follicle, was rarely detected (Figure 4E). The
7 KRT14-positive cell population in EGF and Y-27632-treated iPSC-KC at passage 2
8 reached to 95.9%, as shown by flow cytometric analysis (Figure 4F).

9

10 **Passage-dependent epidermal differentiation of iPSC-KCs for 3D skin**

11 HDK1-K4DT cells had a strong proliferative ability with high expression levels of
12 epithelial markers during the long-term culture period. iPSC-KCs reduced proliferative
13 ability as each passage progressed; however, their terminal differentiation ability
14 increased as each passage progressed (Figure 4B and Supplemental Figure S3A). Cell
15 morphology of iPSC-KCs appeared spindle-like during early passages and became
16 similar to human keratinocytes as the passages progressed (Supplemental Figure S3B).
17 However, a vacuolar degeneration-like structure was observed at passage 5, and the
18 cells ceased to proliferate (Supplemental Figure S3B).

19

20 For the successful construction of 3D skin with iPSC-KCs, we investigated proper
21 passage number of iPSC-KCs with both sufficient expression levels of KRT14 and the
22 ability of cells to grow. Unfortunately, 3D skin was not generated with iPSC-KCs by
23 the same method as HDK1-K4DT. Thus, we increased the initial seeding cell number of
24 iPSC-KCs from 2×10^5 to 1×10^6 and allowed 2 d for the culture period in iPSC-KCs
25 before high Ca^{2+} induction at the air-liquid interface. iPSC-KCs at passage 0
26 constructed epidermis that were negative for ki67, KRT14, p63 and Pan-cytokeratin
27 (Pan-CK) (Supplemental Figure S4). The 3D skin with iPSC-KCs at passage 1 revealed
28 immature epithelial-like tissue that expressed pan-CK and Ki67 but not other epithelial
29 markers, including KRT14 and P63 (Supplemental Figure S4). The 3D skin with
30 iPSC-KCs at later passages (more than passage 4) showed mature keratinocytes with the
31 prickle cell layer that were strongly positive for KRT14, Pan-CK, and involucrin, and
32 weakly positive for Ki67 (Supplemental Figure S4). Finally, we successfully identified

1 the most suitable condition to generate a multilayered epidermis with iPSC-KCs at
2 passage 3. The 3D skin with iPSC-KCs at passage 3 after 14 d of air-liquid cultivation
3 had a multilayered epidermis with the KRT14 in the basal compartment and laminin 5
4 at the dermal-epidermal junction (Figure 5). Moreover, KRT10 was detected in the
5 suprabasal layer, and loricrin and filaggrin, late markers of epidermal differentiation,
6 were also observed in the upper layers of the epidermis. These data suggest that
7 AF-TTTS-iPSCs and AF-T21-iPSCs can be differentiated into fully functional
8 keratinocytes for artificial 3D skin. This success may be attributed to the favorable
9 balance of proliferation and differentiation capacities in iPSC-KCs.

10

11 **Transplantation of 3D skin into MMC fetal rats**

12 A total of 97 fetuses were viable after cesarean section. MMC was present in 83.5% (81
13 of 97) of fetuses exposed to RA. These MMC rats showed a defect in the skin and spine
14 and exposure of the spinal cord (Figure 6A). Cross-sectional analysis confirmed the
15 MMC defects and showed the degenerated spinal cord in rats exposed to RA
16 (Figure 6B). In total, 20 fetal rats were operated on at day 20 of gestation. The 3D skin
17 with iPSC-KCs was transplanted into fetuses across a small incision of the uterine wall
18 following closure of the incision site (Figure 6C). A cesarean section was performed at
19 day 22 of gestation. The survival of rats was lower in the fetal therapy group (15 of 20;
20 80%) compared with non-treated MMC fetus group (61 of 61; 100%). Twelve neonatal
21 rats had a complete or partial skin defect coverage with 3D skin [complete coverage: 4
22 of 20 (20%), incomplete coverage: 8 of 20 (40%)], virtually isolating the spinal cord
23 from direct exposure to the amniotic cavity (Figure 6D). Birth weight and crown-rump
24 length (CRL) were significantly lower in the fetal therapy group than in normal rats and
25 non-treated MMC rats (Figure 6E). Although the transverse length (TL) and vertical
26 length (VL) of the MMC defect size were slightly shorter in the fetal therapy group than
27 in fetuses without therapy, there were no significant differences when the TL and VL
28 were adjusted for overall fetal CRL (Figure 6F).

29

30 **Histological evaluation of 3D skin at transplantation site**

31 Immunohistochemistry of the transplanted artificial skin with iPSC-KCs and
32 HDK1-K4DT demonstrated that the expression of epithelial markers, such as KRT14

1 and p63 was weak, but obviously remained after birth (Figure 6G). Transplanted 3D
2 skin was confirmed using human-specific antigen cytoplasmic protein detected with
3 “stem121”. Moreover, epidermal ingrowth was detected at the edge of the epidermis
4 defect in MMC rats, and the epidermis appeared to be elongated underneath the
5 transplantation site (Supplemental Figure S5).

6

7 **Discussion**

8 This study is designed to obtain preclinical proof of concept for fetal therapy to patients
9 with MMC using autologous iPSCs. Pregnant women with polyhydramnion need to
10 receive amnioreduction therapy, i.e. 1,000 to 2,000 ml of AF is usually aspirated for
11 preventing threatened premature delivery and respiratory discomfort. A large number of
12 AFCs can be obtained from 20 ml of AF by amnioreduction. The sufficient number of
13 AFCs with their prominent proliferation capability leads to successful iPSC generation
14 from patients with lethal disorders, such as TTTS.

15

16 **Artificial Skin with iPSC-epidermal cells and dermal fibroblasts**

17 Epidermal sheet products are applied to patients with skin disorders, such as severe burn,
18 giant congenital melanocytic nevus, vitiligo vulgaris, and epidermolysis bulla (Kamao
19 et al., 2014; Kishi et al., 2010; Lu et al., 2014) and are often used with a combination
20 with cryopreserved allogeneic skin, artificial dermis, non-surgical granulation tissue,
21 meshed/patched autologous skin, and fresh allogeneic skin (Matsumura et al., 2016).
22 Artificial skin with adequate strength is required because not only epidermis but also
23 dermis is absent in the defect site of MMC. Therefore, epidermis alone is not sufficient
24 to cover the defect.

25

26 In addition to the tissue engineering approach with usage of bioengineered products,
27 organoid is formed in vitro in 3D as a miniaturized and simplified version of an organ.
28 The organoid self-organizes in 3D culture through self-renewal and differentiation
29 capacities of pluripotent stem cells, such as iPSCs and ESCs. Organoids, such as eye,
30 gut, liver, and brain, are being developed (Hasegawa et al., 2016; Sasai, 2013; Takebe et
31 al., 2012; Uchida et al., 2016; Yokobori et al., 2016). A skin organoid, however, has not
32 been developed so far to assure strength to cover the defect site of MMC.

1

2 **Challenge of an iPSC therapy to diseased fetus**

3 The first autologous cellular therapy was performed to a patient with macular
4 degeneration with iPSCs generated from skin biopsy (Kamao et al., 2014). Herein, we
5 hypothesize that AFC-derived iPSCs can be used for diseased fetus. The differentiation
6 protocol developed in this study enables earlier induction of keratinocytes from iPSCs
7 than previously reported. However, the window period of acceptable fetal therapy is
8 usually 19–26 weeks of gestation due to fetal condition. Therefore, to perform cellular
9 therapy during pregnancy, allogeneic products with appropriately selected haplotypes
10 may be more feasible because even less than 100 cell lines of iPSCs from banks would
11 be sufficient to cover 90% of the Japanese population (Nakatsuji et al., 2008).

12

13 **Efficient epidermal differentiation of iPSCs with rock inhibitor**

14 The efficient keratinocytic differentiation in a short period was achieved by
15 supplementation with both EGF and a rock inhibitor(Guenou et al., 2009; Itoh et al.,
16 2011; Itoh et al., 2013). Y27632, a rock inhibitor, affects the differentiation and
17 proliferation of various types of stem cells (Joo et al., 2012; Kurosawa, 2012; Watanabe
18 et al., 2007). Moreover, Y27632 enables primary human keratinocytes not only
19 efficiently to bypass senescence but also to increase long-term proliferation (Chapman
20 et al., 2010; Chapman et al., 2014). Furthermore, Y27632 facilitates differentiation of
21 mesenchymal stem cells into keratinocyte-like cells (Li et al., 2015). Likewise,
22 Y-27632-treated iPSC-KCs showed improved cell growth and induced differentiation of
23 human iPSCs into functional keratinocytes that were used for manufacturing of 3D skin.

24

25 EGF is the critical factor for the generation of human KRT15-positive epithelial stem
26 cells, which are capable of differentiating into multiple cell types, such as cells of hair
27 follicles and interfollicular epidermis and KRT14-positive basal cells from human
28 iPSCs (Yang et al., 2014). These are compatible with the results in this study that
29 showed an increased number of KRT14-positive iPSC-KCs and up-regulated expression
30 of the KRT14 gene along with decreased expression of pluripotency markers. In
31 contrast, lack of KRT15 in iPSC-KCs indicates that human iPSC-KCs generated with
32 our protocol comprised a larger proportion of mature keratinocytes than

1 KRT15-positive epithelial stem cells, which may decrease during the induction process.
2 Along with the benefit of EGF, we have to be careful because our differentiation
3 protocol using EGF may induce other types of skin stem cells under certain conditions
4 in 3D culture due to induction of sebocytic lineage with EGF (Zouboulis, 2013).

6 **Fetal therapy to a patient with MMC with 3D skin**

7 Fetal therapy started with patients with TTTS, fetal anemia, and MMC (Adzick and
8 Harrison, 1994; De Lia et al., 1990; Rodeck et al., 1981); however, a standard procedure
9 has not yet been developed (Danzer and Johnson, 2014). As for MMC, laparoscopic
10 surgery to suture skin defects is one of the fetal therapies so far in cases wherein skin
11 defects are not large. Artificial skin needs to be developed due to coverage of large skin
12 defects along with surgical approach. For generation of artificial 3D skin, iPSCs can be
13 efficiently generated from AFCs derived from polyhydramnion in integration-free,
14 xeno-free, and serum-free conditions because AFCs derived from patients with
15 polyhydramnion exhibited prominent proliferative capacity *in vitro*.

16
17 An important limitation of this rat model is the short gestation period of rats without the
18 ability to analyze the longer-term effects of artificial skin *in vivo*. Further studies to
19 analyze the longer-term effect, including regeneration of skin, tumorigenic potential,
20 and neurological prognosis, are required in large animal model. In the fetal therapy
21 strategy, improvement in distal neurological function remains limited because of the
22 failure to reverse neurological injury that occurred prior to the time of repair (Hefez et
23 al., 1990). The transplantation of neural stem cells was reported to improve neurological
24 outcome in an animal model of nerve injury, such as spinal cord injury (Biernaskie et al.,
25 2007; Hu et al., 2010; Sieber-Blum, 2010; Wang et al., 2011). iPSC-derived neural crest
26 stem cells integrate into the injured spinal cord in the fetal lamb model of MMC (Saadai
27 et al., 2013). Additional cell types, such as neural stem cells/neural crest cells, to the
28 artificial skin may be beneficial to a future fetal therapy.

29
30 In this study, we demonstrated a novel fetal MMC therapy that can be achieved by
31 cellular therapy using AFC-derived iPSCs. Our fetal cell treatment is minimally
32 invasive and therefore has the potential to become a novel treatment for MMC.

1 **Acknowledgments**

2 This study was supported by a grant from JSPS KAKENHI (grant number
3 JP15K19665). We are grateful to Dr. Tohru Kiyono, Division of virology chief at
4 National cancer center research institute, for donating the cell line of HDK1-K4DT. We
5 sincerely thank Minoru Ichinose (NCDHD) for performing sectioning. The
6 encyclopedic pathological knowledge of Michoyo Nasu (NCDHD) was gratefully
7 appreciated. I am also grateful to the Centre for Maternal-Fetal, Neonatal and
8 Reproductive Medicine (NCCHD) for AF collection. The authors would like to thank
9 Enago (www.enago.jp) for the English language review.

10

11 **Conflict of Interest**

12 There are no conflicts of interest to declare.

13

1 **Reference**

2

3 Adzick, N.S., and Harrison, M.R. (1994). Fetal surgical therapy. *Lancet* *343*, 897-902.

4 Adzick, N.S., Thom, E.A., Spong, C.Y., Brock, J.W., Burrows, P.K., Johnson, M.P.,
5 Howell, L.J., Farrell, J.A., Dabrowiak, M.E., Sutton, L.N., *et al.* (2011). A randomized
6 trial of prenatal versus postnatal repair of myelomeningocele. *N Engl J Med* *364*,
7 993-1004.

8 Biernaskie, J., Sparling, J.S., Liu, J., Shannon, C.P., Plemel, J.R., Xie, Y., Miller, F.D.,
9 and Tetzlaff, W. (2007). Skin-derived precursors generate myelinating Schwann cells
10 that promote remyelination and functional recovery after contusion spinal cord injury. *J*
11 *Neurosci* *27*, 9545-9559.

12 Bilousova, G., Chen, J., and Roop, D.R. (2011). Differentiation of mouse induced
13 pluripotent stem cells into a multipotent keratinocyte lineage. *J Invest Dermatol* *131*,
14 857-864.

15 Brown, E.G., Saadai, P., Pivetti, C.D., Beattie, M.S., Bresnahan, J.C., Wang, A., and
16 Farmer, D.L. (2014). In utero repair of myelomeningocele with autologous amniotic
17 membrane in the fetal lamb model. *J Pediatr Surg* *49*, 133-137; discussion 137-138.

18 Bruner, J.P., Tulipan, N., Reed, G., Davis, G.H., Bennett, K., Luker, K.S., and
19 Dabrowiak, M.E. (2004). Intrauterine repair of spina bifida: preoperative predictors of
20 shunt-dependent hydrocephalus. *Am J Obstet Gynecol* *190*, 1305-1312.

21 Chapman, S., Liu, X., Meyers, C., Schlegel, R., and McBride, A.A. (2010). Human
22 keratinocytes are efficiently immortalized by a Rho kinase inhibitor. *J Clin Invest* *120*,
23 2619-2626.

24 Chapman, S., McDermott, D.H., Shen, K., Jang, M.K., and McBride, A.A. (2014). The
25 effect of Rho kinase inhibition on long-term keratinocyte proliferation is rapid and
26 conditional. *Stem Cell Res Ther* *5*, 60.

27 Cherry, A.B., and Daley, G.Q. (2012). Reprogramming cellular identity for regenerative
28 medicine. *Cell* *148*, 1110-1122.

29 Cherry, A.B., and Daley, G.Q. (2013). Reprogrammed cells for disease modeling and
30 regenerative medicine. *Annu Rev Med* *64*, 277-290.

31 Danzer, E., and Johnson, M.P. (2014). Fetal surgery for neural tube defects. *Semin Fetal*
32 *Neonatal Med* *19*, 2-8.

- 1 Danzer, E., Schwarz, U., Wehrli, S., Radu, A., Adzick, N.S., and Flake, A.W. (2005).
2 Retinoic acid induced myelomeningocele in fetal rats: characterization by
3 histopathological analysis and magnetic resonance imaging. *Exp Neurol* 194, 467-475.
- 4 De Coppi, P., Bartsch, G., Siddiqui, M.M., Xu, T., Santos, C.C., Perin, L., Mostoslavsky,
5 G., Serre, A.C., Snyder, E.Y., Yoo, J.J., *et al.* (2007). Isolation of amniotic stem cell
6 lines with potential for therapy. *Nat Biotechnol* 25, 100-106.
- 7 De Lia, J.E., Cruikshank, D.P., and Keye, W.R. (1990). Fetoscopic neodymium:YAG
8 laser occlusion of placental vessels in severe twin-twin transfusion syndrome. *Obstet*
9 *Gynecol* 75, 1046-1053.
- 10 Egawa, N., Nakahara, T., Ohno, S., Narisawa-Saito, M., Yugawa, T., Fujita, M., Yamato,
11 K., Natori, Y., and Kiyono, T. (2012). The E1 protein of human papillomavirus type 16
12 is dispensable for maintenance replication of the viral genome. *J Virol* 86, 3276-3283.
- 13 Guenou, H., Nissan, X., Larcher, F., Feteira, J., Lemaitre, G., Saidani, M., Del Rio, M.,
14 Barrault, C.C., Bernard, F.X., Peschanski, M., *et al.* (2009). Human embryonic
15 stem-cell derivatives for full reconstruction of the pluristratified epidermis: a preclinical
16 study. *Lancet* 374, 1745-1753.
- 17 Hasegawa, Y., Takata, N., Okuda, S., Kawada, M., Eiraku, M., and Sasai, Y. (2016).
18 Emergence of dorsal-ventral polarity in ESC-derived retinal tissue. *Development* 143,
19 3895-3906.
- 20 Heffez, D.S., Aryanpur, J., Hutchins, G.M., and Freeman, J.M. (1990). The paralysis
21 associated with myelomeningocele: clinical and experimental data implicating a
22 preventable spinal cord injury. *Neurosurgery* 26, 987-992.
- 23 Hu, Y.F., Gourab, K., Wells, C., Clewes, O., Schmit, B.D., and Sieber-Blum, M. (2010).
24 Epidermal neural crest stem cell (EPI-NCSC)--mediated recovery of sensory function in
25 a mouse model of spinal cord injury. *Stem Cell Rev* 6, 186-198.
- 26 Itoh, M., Kiuru, M., Cairo, M.S., and Christiano, A.M. (2011). Generation of
27 keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced
28 pluripotent stem cells. *Proc Natl Acad Sci U S A* 108, 8797-8802.
- 29 Itoh, M., Umegaki-Arao, N., Guo, Z., Liu, L., Higgins, C.A., and Christiano, A.M.
30 (2013). Generation of 3D skin equivalents fully reconstituted from human induced
31 pluripotent stem cells (iPSCs). *PLoS One* 8, e77673.
- 32 Johnson, M.P., Sutton, L.N., Rintoul, N., Crombleholme, T.M., Flake, A.W., Howell,
33 L.J., Hedrick, H.L., Wilson, R.D., and Adzick, N.S. (2003). Fetal myelomeningocele
34 repair: short-term clinical outcomes. *Am J Obstet Gynecol* 189, 482-487.

- 1 Joo, H.J., Choi, D.K., Lim, J.S., Park, J.S., Lee, S.H., Song, S., Shin, J.H., Lim, D.S.,
2 Kim, I., Hwang, K.C., *et al.* (2012). ROCK suppression promotes differentiation and
3 expansion of endothelial cells from embryonic stem cell-derived Flk1(+) mesodermal
4 precursor cells. *Blood* *120*, 2733-2744.
- 5 Kamao, H., Mandai, M., Okamoto, S., Sakai, N., Suga, A., Sugita, S., Kiryu, J., and
6 Takahashi, M. (2014). Characterization of human induced pluripotent stem cell-derived
7 retinal pigment epithelium cell sheets aiming for clinical application. *Stem Cell Reports*
8 *2*, 205-218.
- 9 Kishi, K., Ninomiya, R., Okabe, K., Konno, E., Katsube, K., Imanishi, N., Nakajima, H.,
10 and Nakajima, T. (2010). Treatment of giant congenital melanocytic nevi with
11 enzymatically separated epidermal sheet grafting. *J Plast Reconstr Aesthet Surg* *63*,
12 914-920.
- 13 Kohl, T., Hering, R., Heep, A., Schaller, C., Meyer, B., Greive, C., Bizjak, G., Buller, T.,
14 Van de Vondel, P., Gogarten, W., *et al.* (2006). Percutaneous fetoscopic patch coverage
15 of spina bifida aperta in the human--early clinical experience and potential. *Fetal Diagn*
16 *Ther* *21*, 185-193.
- 17 Kohl, T., Tchatcheva, K., Merz, W., Wartenberg, H.C., Heep, A., Müller, A., Franz, A.,
18 Stressig, R., Willinek, W., and Gembruch, U. (2009). Percutaneous fetoscopic patch
19 closure of human spina bifida aperta: advances in fetal surgical techniques may obviate
20 the need for early postnatal neurosurgical intervention. *Surg Endosc* *23*, 890-895.
- 21 Kurosawa, H. (2012). Application of Rho-associated protein kinase (ROCK) inhibitor to
22 human pluripotent stem cells. *J Biosci Bioeng* *114*, 577-581.
- 23 Li, C., Zhou, J., Shi, G., Ma, Y., Yang, Y., Gu, J., Yu, H., Jin, S., Wei, Z., Chen, F., *et al.*
24 (2009). Pluripotency can be rapidly and efficiently induced in human amniotic
25 fluid-derived cells. *Hum Mol Genet* *18*, 4340-4349.
- 26 Li, Z., Han, S., Wang, X., Han, F., Zhu, X., Zheng, Z., Wang, H., Zhou, Q., Wang, Y., Su,
27 L., *et al.* (2015). Rho kinase inhibitor Y-27632 promotes the differentiation of human
28 bone marrow mesenchymal stem cells into keratinocyte-like cells in xeno-free
29 conditioned medium. *Stem Cell Res Ther* *6*, 17.
- 30 Lu, N., Xu, A., and Wu, X. (2014). Follow-up study of vitiligo patients treated with
31 autologous epidermal sheet transplants. *J Dermatolog Treat* *25*, 200-204.
- 32 Mangels, K.J., Tulipan, N., Bruner, J.P., and Nickolaus, D. (2000). Use of bipedicular
33 advancement flaps for intrauterine closure of myeloschisis. *Pediatr Neurosurg* *32*,
34 52-56.
- 35 Maslen, C.L., Babcock, D., Robinson, S.W., Bean, L.J., Dooley, K.J., Willour, V.L., and

- 1 Sherman, S.L. (2006). CRELD1 mutations contribute to the occurrence of cardiac
2 atrioventricular septal defects in Down syndrome. *Am J Med Genet A* 140, 2501-2505.
- 3 Matsumura, H., Matsushima, A., Ueyama, M., and Kumagai, N. (2016). Application of
4 the cultured epidermal autograft "JACE(®)" for treatment of severe burns: Results of a
5 6-year multicenter surveillance in Japan. *Burns* 42, 769-776.
- 6 McLone, D.G., and Knepper, P.A. (1989). The cause of Chiari II malformation: a
7 unified theory. *Pediatr Neurosci* 15, 1-12.
- 8 Metallo, C.M., Ji, L., de Pablo, J.J., and Palecek, S.P. (2008). Retinoic acid and bone
9 morphogenetic protein signaling synergize to efficiently direct epithelial differentiation
10 of human embryonic stem cells. *Stem Cells* 26, 372-380.
- 11 Michejda, M. (1984). Intrauterine treatment of spina bifida: primate model. *Z*
12 *Kinderchir* 39, 259-261.
- 13 Nakatsuji, N., Nakajima, F., and Tokunaga, K. (2008). HLA-haplotype banking and iPS
14 cells. *Nat Biotechnol* 26, 739-740.
- 15 Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H.,
16 Nakagawa, M., Tanabe, K., Tezuka, K., *et al.* (2011). A more efficient method to
17 generate integration-free human iPS cells. *Nat Methods* 8, 409-412.
- 18 Pham, C., Greenwood, J., Cleland, H., Woodruff, P., and Maddern, G. (2007).
19 Bioengineered skin substitutes for the management of burns: a systematic review. *Burns*
20 33, 946-957.
- 21 Rodeck, C.H., Kemp, J.R., Holman, C.A., Whitmore, D.N., Karnicki, J., and Austin,
22 M.A. (1981). Direct intravascular fetal blood transfusion by fetoscopy in severe Rhesus
23 isoimmunisation. *Lancet* 1, 625-627.
- 24 Saadai, P., Wang, A., Nout, Y.S., Downing, T.L., Lofberg, K., Beattie, M.S., Bresnahan,
25 J.C., Li, S., and Farmer, D.L. (2013). Human induced pluripotent stem cell-derived
26 neural crest stem cells integrate into the injured spinal cord in the fetal lamb model of
27 myelomeningocele. *J Pediatr Surg* 48, 158-163.
- 28 Sasai, Y. (2013). Next-generation regenerative medicine: organogenesis from stem cells
29 in 3D culture. *Cell Stem Cell* 12, 520-530.
- 30 Sieber-Blum, M. (2010). Epidermal neural crest stem cells and their use in mouse
31 models of spinal cord injury. *Brain Res Bull* 83, 189-193.
- 32 Sivan, P.P., Syed, S., Mok, P.L., Higuchi, A., Murugan, K., Alarfaj, A.A., Munusamy,
33 M.A., Awang Hamat, R., Umezawa, A., and Kumar, S. (2016). Stem Cell Therapy for

- 1 Treatment of Ocular Disorders. *Stem Cells Int* 2016, 8304879.
- 2 Suprynowicz, F.A., Upadhyay, G., Krawczyk, E., Kramer, S.C., Hebert, J.D., Liu, X.,
3 Yuan, H., Chelvaraju, C., Clapp, P.W., Boucher, R.C., *et al.* (2012). Conditionally
4 reprogrammed cells represent a stem-like state of adult epithelial cells. *Proc Natl Acad*
5 *Sci U S A* 109, 20035-20040.
- 6 Sutton, L.N., Adzick, N.S., Bilaniuk, L.T., Johnson, M.P., Crombleholme, T.M., and
7 Flake, A.W. (1999). Improvement in hindbrain herniation demonstrated by serial fetal
8 magnetic resonance imaging following fetal surgery for myelomeningocele. *JAMA* 282,
9 1826-1831.
- 10 Takebe, T., Sekine, K., Suzuki, Y., Enomura, M., Tanaka, S., Ueno, Y., Zheng, Y.W., and
11 Taniguchi, H. (2012). Self-organization of human hepatic organoid by recapitulating
12 organogenesis in vitro. *Transplant Proc* 44, 1018-1020.
- 13 Tatsumi, Y., Sugimoto, N., Yugawa, T., Narisawa-Saito, M., Kiyono, T., and Fujita, M.
14 (2006). Deregulation of Cdt1 induces chromosomal damage without rereplication and
15 leads to chromosomal instability. *J Cell Sci* 119, 3128-3140.
- 16 Tsai, M.S., Lee, J.L., Chang, Y.J., and Hwang, S.M. (2004). Isolation of human
17 multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel
18 two-stage culture protocol. *Hum Reprod* 19, 1450-1456.
- 19 Tsunenaga, M., Kohno, Y., Horii, I., Yasumoto, S., Huh, N.H., Tachikawa, T., Yoshiki,
20 S., and Kuroki, T. (1994). Growth and differentiation properties of normal and
21 transformed human keratinocytes in organotypic culture. *Jpn J Cancer Res* 85, 238-244.
- 22 Tubbs, R.S., Chambers, M.R., Smyth, M.D., Bartolucci, A.A., Bruner, J.P., Tulipan, N.,
23 and Oakes, W.J. (2003). Late gestational intrauterine myelomeningocele repair does not
24 improve lower extremity function. *Pediatr Neurosurg* 38, 128-132.
- 25 Tulipan, N., Hernanz-Schulman, M., Lowe, L.H., and Bruner, J.P. (1999). Intrauterine
26 myelomeningocele repair reverses preexisting hindbrain herniation. *Pediatr Neurosurg*
27 31, 137-142.
- 28 Tulipan, N., Sutton, L.N., Bruner, J.P., Cohen, B.M., Johnson, M., and Adzick, N.S.
29 (2003). The effect of intrauterine myelomeningocele repair on the incidence of
30 shunt-dependent hydrocephalus. *Pediatr Neurosurg* 38, 27-33.
- 31 Uchida, H., Machida, M., Miura, T., Kawasaki, T., Okazaki, T., Sasaki, K., Sakamoto,
32 S., Ohuchi, N., Kasahara, M., Umezawa, A., *et al.* (2016). A xenogeneic-free system
33 generating functional human gut organoids from pluripotent stem cells. *JCI Insight*. In
34 press.

- 1 Veraitch, O., Kobayashi, T., Imaizumi, Y., Akamatsu, W., Sasaki, T., Yamanaka, S.,
2 Amagai, M., Okano, H., and Ohyama, M. (2013). Human induced pluripotent stem
3 cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vivo.
4 *J Invest Dermatol* *133*, 1479-1488.
- 5 Walsh, D.S., Adzick, N.S., Sutton, L.N., and Johnson, M.P. (2001). The Rationale for in
6 utero repair of myelomeningocele. *Fetal Diagn Ther* *16*, 312-322.
- 7 Wang, A., Tang, Z., Park, I.H., Zhu, Y., Patel, S., Daley, G.Q., and Li, S. (2011).
8 Induced pluripotent stem cells for neural tissue engineering. *Biomaterials* *32*,
9 5023-5032.
- 10 Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T.,
11 Takahashi, J.B., Nishikawa, S., Muguruma, K., and Sasai, Y. (2007). A ROCK inhibitor
12 permits survival of dissociated human embryonic stem cells. *Nat Biotechnol* *25*,
13 681-686.
- 14 Watanabe, M., Jo, J., Radu, A., Kaneko, M., Tabata, Y., and Flake, A.W. (2010). A tissue
15 engineering approach for prenatal closure of myelomeningocele with gelatin sponges
16 incorporating basic fibroblast growth factor. *Tissue Eng Part A* *16*, 1645-1655.
- 17 Watanabe, M., Li, H., Roybal, J., Santore, M., Radu, A., Jo, J., Kaneko, M., Tabata, Y.,
18 and Flake, A. (2011). A tissue engineering approach for prenatal closure of
19 myelomeningocele: comparison of gelatin sponge and microsphere scaffolds and
20 bioactive protein coatings. *Tissue Eng Part A* *17*, 1099-1110.
- 21 Yang, R., Zheng, Y., Burrows, M., Liu, S., Wei, Z., Nace, A., Guo, W., Kumar, S.,
22 Cotsarelis, G., and Xu, X. (2014). Generation of folliculogenic human epithelial stem
23 cells from induced pluripotent stem cells. *Nat Commun* *5*, 3071.
- 24 Yokobori, T., Suzuki, S., Miyazaki, T., Sohda, M., Sakai, M., Tanaka, N., Ozawa, D.,
25 Hara, K., Honjo, H., Altan, B., *et al.* (2016). Intestinal epithelial culture under an
26 air-liquid interface: a tool for studying human and mouse esophagi. *Dis Esophagus* *29*,
27 843-847.
- 28 You, Q., Cai, L., Zheng, J., Tong, X., Zhang, D., and Zhang, Y. (2008). Isolation of
29 human mesenchymal stem cells from third-trimester amniotic fluid. *Int J Gynaecol*
30 *Obstet* *103*, 149-152.
- 31 Zouboulis, C.C. (2013). Epidermal growth factor receptor and the sebaceous gland. *Exp*
32 *Dermatol* *22*, 695-696.
33
34

1 **Figure Legends**

2 **Figure 1: Characterization of human amniotic fluid cells (AFCs) derived from**
3 **patients with Down syndrome and twin–twin transfusion syndrome**
4 **(TTTS)-associated polyhydramnion.**

5 (A) Phase-contrast microscopic analysis for cell morphology in AFCs from patients
6 with TTTS (TTTS-AFCs) and Down syndrome (T21-AFCs). Mesenchymal stem
7 cell-like colonies appeared on the sixth day of culturing and 10th day of culturing. Scale
8 bar is 500 μ m. (B) Flow cytometric analysis for CD29, CD44, CD73, CD117, CD14,
9 CD19, CD34, human leukocyte antigen (HLA)-ABC, and HLA-DR. Isotype controls
10 are shown in each panel. (C) Quantitative RT-PCR analysis for expression of OCT3/4,
11 NANOG, SOX2, TERT, and DNMT3B. Values are shown as mean \pm standard
12 deviation from three independent experiments.

13

14 **Figure 2: Generation of iPSCs from patients with Down syndrome (T21) and**
15 **twin–twin transfusion syndrome (TTTS).**

16 (A) Phase contrast microscopic view of AF-TTTS-iPSC and AF-T21-iPSCs with
17 embryonic stem cell (ESC)-like morphology growing on a feeder-free vitronectin
18 surface (left panels). AF-TTTS-iPSCs and AF-T21-iPSCs are positive for alkaline
19 phosphatase staining (ALP) (right panels). Scale bar is 500 μ m.

20 (B) Immunocytochemical analysis of stem cell markers, i.e. OCT3/4, NANOG, SOX2,
21 SSEA-4, TRA-1-60, and TRA-1-81 in AF-TTTS-iPSCs and AF-T21-iPSCs colonies.
22 AF-TTTS-iPSCs and AF-T21-iPSCs expressed these pluripotent markers. Nuclei were
23 stained with DAPI (blue). Scale bar is 100 μ m

24 (C) qRT-PCR analysis on the endogenous expression levels of OCT3/4, NANOG,
25 SOX2, TERT, and DNMT3B in AF-TTTS-iPSCs and AF-T21-iPSCs. The expression
26 levels of these stem cell markers in AF-TTTS-iPSCs and AF-T21-iPSCs are
27 comparable to those in human ESCs (SEES2).

28 (D) *In vitro* differentiation of AF-TTTS-iPSCs and AF-T21-iPSCs into three germ
29 layers. After embryoid body formation, iPSCs were stained with antibodies to α -smooth
30 muscle actin (α SMA) (a mesodermal marker), α -fetoprotein (AFP) (an endodermal

1 marker), and beta-III tubulin (TUJ-1) (an ectodermal marker). Scale bar is 100 μ m.
2 (E) *in vivo* differentiation of AF-TTTS-iPSCs and AF-T21-iPSCs into three germ layers.
3 Teratomas were harvested 6–8 weeks after subcutaneous injection of iPSC cells into nude
4 mice. Various tissues, such as neural epithelium (ectodermal), cartilage (mesoderm),
5 and liver (endoderm), were found. Scale bar is 200 μ m.
6 (F) Karyotypic analysis in AF-TTTS-iPSCs. AF-TTTS-iPSCs had normal karyotypes
7 (46, XY).
8 (G) Karyotypic analysis in AF-T21-iPSCs. AF-T21-iPSCs had typical trisomy
9 karyotypes (47, XX, +21).

10

11 **Figure 3: Establishment of differentiation protocol of iPSCs into the lineage of**
12 **keratinocytes.**

13 (A) A schematic of the three differentiation protocols for generation of keratinocytes
14 from iPSCs. Protocols A and B differed in the coating agents. Protocol C was
15 performed via embryoid body (EB) formation (iPSC-EB). DKSFM, defined
16 keratinocyte serum-free medium; RA, retinoic acid; BMP4, bone morphogenetic protein
17 4; VTN, vitronectin; E8, Essential 8; ESM, ESC medium.

18 (B) Beta-galactosidase staining of iPSC-KCs at the indicated time points (days 14 and
19 21). Cell senescence was observed at day 21 of the induction. Scale bar is 100 μ m.

20 (C) iPSC-derived keratinocytes with different methods (protocols A, B, and C) at
21 passage 2 were immunocytochemically stained with anti-keratin 14 (KRT14) antibody.
22 Homogenous keratinocyte-like cells were stained in protocol A. Scale bar is 100 μ m.

23 (D) The number of cells positive for KRT14. The number of KRT 14-positive cells
24 were highest in protocol A (48.08%), compared with protocol B (39.24%) and protocol
25 C (23.62%). Data are shown as mean \pm SD of the cell number from three independent
26 experiments. KRT14: keratin 14. ****** $P < 0.01$.

27 (E) The growth rate of iPSC-derived keratinocytes with different treatment. A
28 combination of Y-27632- and epidermal growth factor accelerated cell growth. EGF,
29 epidermal growth factor; DKSFM, defined keratinocyte serum free medium; KSFM,
30 keratinocyte serum free medium.

31 (F) qRT-PCR analysis of KRT14 and stem cell markers, i.e. OCT3/4 and NANOG, in
32 iPSC-KCs at passage 2. KRT14 expression increased by the addition of epidermal

1 growth factor (EGF). Data shown are mean \pm SD of the expressions from three
2 independent experiments.
3 (G) qRT-PCR analysis of KRT14 and stem cell markers in iPSC-KCs at passage 0.
4 Gene expression levels of OCT3/4 and NANOG increased in the presence of Y-27632,
5 whereas the KRT14 expression level remained unchanged by the treatment of Y-27632.
6 Data are presented as a mean \pm SD of three independent experiments.
7 (H) A schematic of the final protocol design for differentiation of iPSCs into
8 keratinocytes. iPSC-KC, iPSC-derived keratinocytes; KSFM, keratinocyte serum-free
9 medium; DKSFM, defined keratinocyte serum-free medium; RA, retinoic acid; BMP4,
10 bone morphogenetic protein 4.

11

12 **Figure 4: Characterization of a homogeneous population of keratinocytes derived**
13 **from induced pluripotent stem cells (iPSCs).**

14 (A) Phase-contrast microscopic analysis of human dermal keratinocytes
15 (HDK1-K4DT) and keratinocytes derived from AF-T21-iPSCs (T21-iPSC-KC)
16 and AF-TTTS-iPSCs (TTTS-iPSC-KC). Both iPSC-derived keratinocytes showed
17 human keratinocyte-like morphology. Scale bar is 500 μ m.
18 (B) qRT-PCR analysis of keratin 14 (KRT14) at each passage.
19 (C) qRT-PCR analysis of epithelial markers, i.e., KRT14, KRT18, and Δ NP63, and
20 stem cell markers, i.e. OCT3/4 and NANOG, in human iPSC-KCs at passage 4.
21 The epithelial marker expression levels in iPSC-KCs were similar to those of
22 HDK1-K4DT.
23 (D) qRT-PCR analysis of terminal differentiation markers, i.e. INVOLUCRIN and
24 FILAGGRIN. T21-iPSC-KCs showed higher expression levels of INVOLUCRIN
25 and FILAGGRIN than TTTS-iPSC-KCs did.
26 (E) Immunofluorescence of epithelial markers, i.e. KRT14, p63, laminin 5, involucrin,
27 KRT10, and KRT15. Under the high-calcium condition, iPSC-KCs expressed
28 involucrin and KRT10 at a higher frequency, indicating accelerated epidermal
29 differentiation. Scale bar is 100 μ m.
30 (F) Flow cytometric analysis of KRT14 in iPSC-KCs at passage 2. Isotype controls are
31 included in each panel.

32

1 **Figure 5: Three-dimensional (3D) cultured skin equivalents using iPSC-KCs.**

2 Upper panels: Histology of 3D skin with T21-iPSC-KCs, TTTS-iPSC-KCs, or
3 HDK1-K4DT.
4 Lower panes: Immunohistochemical analysis with antibodies to KRT14, p63, Pan-CK,
5 involucrin, laminin 5, loricrin, KRT10, and filaggrin. The multilayered epidermis
6 expressed KRT14, involucrin, laminin 5, Pan-CK, loricrin, KRT10, and filaggrin in
7 artificial skin, indicating that iPSC-KCs terminally differentiate in these skin
8 equivalents. Scale bar is 100 μ m.
9

10 **Figure 6: The rat model of myelomeningocele (MMC) with application of artificial**
11 **skin.**

12 (A) Gross pathology images of the MMC lesion site at birth in a normal rat (upper-left
13 panel) and MMC rat (upper-right and lower panels). MMC rat shows defects in
14 skin (upper-right) and spine (lower-left) and exposure of spinal cord (lower-right).
15 (B) Cross-sectional images of spinal cord at lumbar levels of a normal rat and MMC
16 rat. Scale bar is 2 mm.
17 (C) Gross view of the intrauterine transplantation of artificial skin. Representative
18 images of major steps of the MMC repair process in the fetal rat model. A MMC
19 defect site was identified through the uterus (upper-left panel). A small incision of
20 the uterus was made just above the defect site, following which artificial skin was
21 transplanted (upper-right panel). Finally, the uterine wall was closed over the
22 defect (lower panels).
23 (D) Gross views of neonatal rat with myelomeningocele (MMC) at birth (E22).
24 Representative photograph in incomplete closure (upper panel) and complete
25 closure (lower panel) after artificial skin application at day 20.
26 (E) Birth weight (BW) and cranio-caudal length (CRL) of normal neonatal and
27 neonatal MMC rats with or without fetal therapy. MMC rats with fetal therapy
28 group were born with smaller BW and CRL compared to normal rats or
29 non-treated MMC rats. $\star\star P < 0.01$.
30 (F) Comparison of MMC defect size between neonatal MMC rats with fetal treatment
31 and rats without therapy. There were no significant differences in the MMC size by

1 fetal therapy when adjusted for the CRL. TL, transverse length; VL, vertical length.

2 * $P < 0.05$. NS, not significant.

3 (G) Expression profile of epidermal markers and short-term *in vivo* effect on
4 regeneration of rat skin defect in artificial skin. Transverse section through the
5 myelomeningocele defect 2 d after a transplantation of artificial skin with
6 iPSC-KC epidermis. The expressions of epidermal markers, i.e. KRT14, p63,
7 pan-cytokeratin (Pan-CK) and stem121, were analyzed in artificial skin with
8 HDK1-K4DT, TTTS-iPSC-KCs, or T21-iPSC-KCs. Scale bar is 100 μm .

9

1 **Supplemental Figure S1. Teratoma formation of in amniotic fluid cells from**
2 **patients with Down syndrome (AF-T21-iPSC) in vivo**

- 3 (A) Neuroblastoma-like tissue
4 (B) Liver tissue with vacuolar structure
5 (C) STR analysis of AF-T21-iPSC, T21-AFC, AF-TTTS-iPSC, and TTTS-AFC. Short
6 tandem repeat (STR) profiling was performed by BEX CO., LTD, Tokyo, Japan.
7 The 16 loci analyzed by the PowerPlex 1.2 system (Promega, Madison, WI, USA)
8 was composed of D3S1358, TH01, D21S11, D18S51, Penta E, D5S818, D13S317,
9 D7S820, D16S539, CSF1PO, Penta D, AMEL, vWA, D8S1179, TPOX, and FGA.
10 T21-AFC and TTTS-AFC were parental cells of AF-T21-iPSC and
11 AF-TTTS-iPSC, respectively.

12

13 **Supplemental Figure S2. Establishment of differentiation protocol of iPSCs into the**
14 **lineage of keratinocytes**

- 15 (A) Flow cytometric analysis of KRT14 in iPSC-KCs at passage 2 (gray) and at passage
16 0 (open). iPSC-KCs were exposed to Y-27632 and EGF.
17 (B) Flow cytometric analysis of SSEA4 in T21-iPSC-KCs. T21-iPSC-KCs at passage 1
18 were exposed to Y27632 alone or Y27632 and EGF for one week and then applied
19 to the flow cytometric analysis. Undifferentiated AF-T21-iPSCs were also shown in
20 black for reference. Isotype control is included at each panel.
21 (C) qRT-PCR analysis of the KRT14 transcripts in iPSC-KCs maintained either in a
22 medium of DKSFM or CNT-PR with EGF and Y27632. The KRT14 gene
23 expression level was higher with the use of DKSFM than with the use of CNT-PR
24 medium. Data are presented as a mean \pm SD of three independent experiments.

25

26 **Supplemental Figure S3: Characterization of T21-iPSC-KCs at different passage**
27 **number**

- 28 (A) The growth rate of T21-iPSC-KCs with the different passage number. Growth rate
29 was reduced as each passage progressed. The initial cell number was 1×10^5 /well,
30 and cell number was counted at the indicated days after cell seeding.

1 (B) Cell morphology of T21-iPSC-KCs in different passage number. iPSC-KCs at
2 early passage exhibited spindle cell morphology (iPSC-KC at P1-2) and became
3 keratinocytic (iPSC-KC at P3-4). In later passages, keratinocyte-like cells with a
4 vacuolar degeneration (iPSC-KC at P5-6) were observed.

5

6 **Supplemental Figure S4. Immunohistochemical analysis on three-dimensional (3D)**
7 **culture of iPSC-KCs at different passages**

8 iPSC-KCs at passage 0 were negative for KRT14, p63, pan-cytokeratin (Pan-CK), and
9 Ki67. iPSC-KCs at passage 1 became positive for pan-CK and Ki67 but not for KRT14
10 and p63. iPSC-KCs at passage 5 were positive for KRT14, Pan-CK, and involucrin but
11 not for p63, indicating terminal differentiation of epidermis in the 3D-culture.

12

13 **Supplemental Figure S5. Short-term in vivo effect on regeneration of rat skin defect**
14 **with iPSC-KC artificial skin**

15 Epidermal ingrowth from the edge of MMC defect was observed underneath the
16 artificial skin under low magnification (A) and high magnification (B). Scale bar is 500
17 μm .

18




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6